Something strange is happening in American medicine.
Two drug classes—GLP-1 receptor agonists like Ozempic and Wegovy, and their cousin tirzepatide sold as Mounjaro and Zepbound—have gone from diabetes treatments to cultural phenomena in under five years.
Roughly one in eight American adults has now tried one, according to KFF polling, and the numbers keep climbing.
But here's the question almost nobody in the mainstream press is asking: what happens when millions of people take a drug that mimics a gut hormone, for years, while the long-term data is still being written?
Big pharma spent decades chasing a blockbuster weight loss pill and failing—remember fen-phen?
That disaster in the 1990s ended with heart valve damage and billion-dollar lawsuits.
The industry learned something important: the money isn't just in the drug.
Novo Nordisk and Eli Lilly have watched their market caps balloon into the hundreds of billions.
Compounding pharmacies flooded the market with cheaper copycats until the FDA cracked down.
Telehealth startups appeared overnight, prescribing these drugs after a five-minute video call.
Everyone gets a cut—except, notably, the patient who has to stay on the drug indefinitely or watch the weight return, as clinical trials have repeatedly shown.
These drugs are being marketed for everything now—heart health, sleep apnea, addiction, even Alzheimer's research.
Some of that science is genuinely promising.
But when a single molecule is pitched as a solution to a dozen unrelated conditions, that's not medicine anymore.
Meanwhile, the FDA's adverse event reporting system has logged thousands of complaints—gastroparesis, pancreatitis, gallbladder issues, muscle loss.
The agency added a warning about suicidal thoughts, then walked it back.
Others quietly worry we're running a nationwide experiment without a control group.
And here's the dot most people miss: the same financial structures that brought us the opioid crisis—aggressive marketing, loose prescribing, profit over precaution—are now pointed at weight loss.
But "it works" and "we understand what it does over twenty years" are very different claims, and only one of them is being sold to you. **The takeaway:** Question the hype, not just the skeptics.
When a treatment becomes a trillion-dollar industry before the long-term science is settled, the burden of proof should shift—and right now, it's sitting comfortably on the wrong side of the ledger.
Final Thoughts
Stay curious, read the labels, and ask who profits when you never stop needing the product.